Press "Enter" to skip to content

AstraZeneca’s Imfinzi fails to meet main goals in head and neck cancer study

AstraZeneca Plc’s immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head and neck cancer, the London-listed drugmaker said on Friday.

Original source:

Also Read:   Novartis gets U.S. approval for new drug to treat multiple sclerosis